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The hematopoietic proto-oncogene vav has been characterized as a Rac1-GDP/GTP exchanger protein which
regulates cytoskeletal reorganization as well as signaling pathways leading to the activation of stress-activated
protein kinases (SAPK/JNKs). Furthermore, vav overexpression enhances basal and T-cell receptor (TCR)-
mediated stimulation of the nuclear factor of activated T cells (NFAT). We report here the interaction between
Vav and hSiah2, a mammalian homolog of Drosophila Seven in absentia (Sina) that has been implicated in R7
photoreceptor cell formation during Drosophila eye development via the proteasome degradation pathway. Vav
and hSiah2 interact in vitro and in vivo and colocalize in the cytoplasm of hematopoietic cells. The Src
homology domain of Vav and the C-terminal region of hSiah2 are required for this interaction. We provide
evidence for a negative regulation by hSiah2 of Vav-induced basal and TCR-mediated NFAT-dependent
transcription. Overexpression of hSiah2 also inhibits the onco-Vav-induced JNK activation. Although the Vav-
interacting domain is located in the C-terminal portion of hSiah2, the N-terminal region of hSiah2 is necessary
for the inhibitory role that seems to be independent of the proteasome degradation.
The vav proto-oncogene product, p95vav, is expressed pri-
marily in cells of hematopoietic origin (40). The oncogenic
form arises from the deletion of 67 N-terminal amino acids of
c-Vav and induces tumors in nude mice (15, 41). The primary
structure of Vav has several structural motifs found in proteins
involved in cell signaling, e.g., an N-terminal leucine-rich re-
gion, an acidic domain, a Dbl homology (DH) domain, a pleck-
strin homology domain, a cysteine-rich sequence and a proline-
rich sequence, two Src homology (SH3) domains flanking a
single SH2 domain, and, finally, two putative nuclear localiza-
tion sequences (59). Indeed, it has been demonstrated that Vav
interacts, via its SH3 domains, with different cytoplasmic pro-
teins, such as Grb2 (53, 70), heterogeneous ribonucleoprotein
(hnRNP) K (11, 31), the focal adhesion protein zyxin (33), and
Cbl-b (10). Moreover, we described the interactions of the
C-SH3 domain of Vav with Ku-70 and hnRNP C, two predom-
inantly nuclear proteins (58, 60).
Despite the numerous partners described, the precise func-
tion of Vav in cell-signaling pathways is unclear. Upon stimu-
lation via immune receptors (T-cell receptor [TCR], B-cell
receptor [BCR], and FcRs) or various cytokine or growth fac-
tor receptors (cKit, Epo, interleukin-2 [IL-2], IL-3, interferon,
epidermal growth factor, platelet-derived growth factor, and
others), Vav is rapidly and transiently tyrosine phosphorylated
(46, 59). Both Src and Syk/Zap70 family kinases have been
implicated in Vav phosphorylation (19, 42). Biochemical evi-
dence has shown that activated Vav catalyzes, via its DH do-
main, the conversion of Rac1 protein, a member of the Rho
family of GTPases, to the active GTP-bound state (18, 29, 51).
Rac1 activation leads in turn to the stimulation of the JNK
pathway (17). However, recent in vivo studies on vav2/2 mice
cast doubt on the role of Vav in JNK activation (24, 35).
Previous studies on vav2/2 mice also indicated impaired T-cell
development and a poor proliferation of mature T cells with a
reduced response to stimulation through the TCR (25, 67, 72).
Overexpression of vav seems to cooperate with Syk (19) and
SLP76 (69) to synergistically induce basal and TCR-activated
transcription of either the IL-2 gene or reporter constructs
containing binding sites for nuclear factor of activated T cells
(NFAT) present in the IL-2 promoter (68). Recent findings
from vav2/2-activated lymphoid cells also showed the absence
of IL-2 transcription even though the JNK activity was still
normal (24, 35). These experiments demonstrated that Vav is
an effector molecule that functions downstream of a variety of
hematopoietic cell receptors. Finally, Vav2, a protein highly
homologous to Vav but with a more ubiquitous expression and
poorly expressed in hematopoietic cells, has been identified. It
has been proposed that this protein may have Vav-like func-
tions in nonhematopoietic cells (30, 64).
To further investigate the role of Vav, we attempted to
identify proteins that bind to its Src homology domains (SH3-
SH2-SH3) by the yeast two-hybrid system. We identified hSiah2,
a human homolog of Drosophila Seven in absentia (Sina) (12),
a ring finger (C3HC4)-containing protein that is required for
the correct integration of signal transduction downstream of
the tyrosine kinase receptor Sevenless (sev) and the Ras/Raf
mitogen-activated protein kinase (MAPK) pathway during
Drosophila R7 photoreceptor development (9, 13, 22, 26, 43).
Recently it was shown that Sina acts together with Phyllopod
(PHYL), induced by the Ras pathway, to target the repressor
of cell fate determination Tramtrack (TTK) for degradation by
the proteasome pathway (45, 66). Three highly conserved mu-
rine sina homologs (Siah1A, Siah1B, and Siah2) and two hu-
man homologs (hSiah1 and hSiah2) have been described (1, 20,
34, 37). Although the function of the mammalian Siah proteins
has not been elucidated, recent studies suggested that they
might be involved in ubiquitin-mediated proteolysis of several
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proteins (38, 71), as well as in growth arrest and p53-induced
apoptosis (2, 47, 49).
In this study, we showed that Vav and hSiah2 interact both
in vitro and in coimmunoprecipitation ex vivo experiments. We
determined that the C-terminal half of hSiah2 and the entire
SH3-SH2-SH3 region of Vav are critical for binding. By im-
munofluorescence studies, we showed that the two proteins
colocalize in the cytoplasm of hematopoietic cells. We further
demonstrated that pathways stimulated by Vav, namely, induc-
tion of NFAT-dependent transcription and onco-Vav-mediat-
ed activation of JNK, are largely impaired in cells overexpress-
ing hSiah2. This inhibition is modulated by the N-terminal
region of hSiah2 and does not involve ubiquitin-mediated pro-
teolysis, a function previously suggested for hSiah2.
MATERIALS AND METHODS
Plasmids. SHVAV containing SH3-SH2-SH3 domains (residues 623 to 837 of
Vav) was PCR amplified from pKLS1 (provided by M. Barbacid, Madrid, Spain,
and X. R. Bustelo, New York, N.Y.) and fused to the DNA-binding domain of
LexA in pVJL10 (58). pGEX-v240 and pGEX-v460 were obtained by cloning the
v240 and v460 cDNA fragments, respectively, from pGAD-v240 (amino acids
[aa] 13 to 324) and pGAD-v460 (aa 105 to 324) into the EcoRI-NotI sites of
pGEX-4T2 (Pharmacia Biotech Inc.). Constructs encoding a truncated form of
hSiah2 (pGEX-v240Da and pGEX-v240Db) were obtained by PCR amplification
from pGAD-v240 with appropriate oligonucleotides (139 to 1555 and 139 to
1475, respectively) followed by ligation into BamHI-SalI sites of pGEX-4T2.
Expression plasmids of myc-tagged hSiah2 cDNA fragments were generated by
cloning the corresponding EcoRI-NotI fragments from pGAD-v240 and pGAD-
v460 into a pcDNA3-derived plasmid, pCAN-M2, to generate pCAN-v240 and
pCAN-v460, respectively. The full-length hSiah2 was generated by replacing the
SpeI-DraIII fragment of pBK-CMV v240 with a PCR fragment amplified from
human genomic DNA by using a 59 primer in the noncoding sequence of mouse
Siah2 (this sequence was highly conserved among mouse Siah and hSiah1) and
a 39 internal primer of the v240 clone (nucleotides 361 to 383). pKES-Vav is a
pcDNA3-derived plasmid containing a full-length mouse cDNA under the con-
trol of the cytomegalovirus promoter (1a). pEF-Myc-tagged Vav was kindly
provided by A. Altman (San Diego, Calif.). pEF-Myc-tagged onco-Vav was
obtained by replacing the Vav EcoRI-BstXI fragment with the corresponding
sequence from pJC7 (15). The NFAT-luciferase reporter construct (kindly pro-
vided by O. Acuto, Paris, France) was derived from the pUBT-luc plasmid (21)
and contained the luciferase gene under the control of the human IL-2 promoter
NFAT-binding site (23). pSV-bgal vector (Promega) contained the b-galactosi-
dase gene driven by the simian virus 40 promoter. HA-JNK and pGEX-cJun
were provided by P. Crespo (Santander, Spain). pBK-CMV hSiah1 was provided
by R. B. Amson (Paris, France).
Yeast two-hybrid system. Saccharomyces cerevisiae L40 (MATa trp1 leu2 his3
LYS::lexA-HIS3 URA3::lexA-lacZ) was grown at 30°C in YPD medium (1% yeast
extract, 2% polypeptone, 2% glucose) and sequentially cotransformed by the
lithium acetate method (65) with pVJL10-SHVAV and a cDNA library from
Jurkat cells fused to the GAL4 activation domain in pGAD1318 (58). Double
transformants were plated on yeast dropout medium lacking Trp, Leu, His, Lys,
and Ura (65). After 5 days at 30°C, colonies were patched on the same medium
and replica plated on Whatman 40 filters to test for b-galactosidase activity (8).
Positive clones were rescued and tested for specificity by retrotransformation
into L40 either with pVJL10-SHVAV or with extraneous targets (pLexA-Rasv12
or pLex-Lamin).
Sequences of cDNA inserts from positive clones of the two-hybrid screen were
obtained for both strands with an automatic sequencer (Applied Biosystems
model 373A) by the dideoxy-termination method of Sanger et al. (62). Sequence
comparisons were done with the FASTA program.
Cell culture, transfection, and antibodies. Jurkat cells or simian virus 40
T-antigen (T-Ag)-transfected Jurkat cells (provided by G. Baier, Innsbruck,
Austria) were grown in RPMI 1640 medium (Gibco) supplemented with 10%
heat-inactivated fetal calf serum (Boehringer Mannheim), 2 mM L-glutamine,
penicillin, and streptomycin in a 5% CO2 humidified atmosphere at 37°C. For
T-Ag Jurkat cells, the medium was supplemented with 2 mg of Geneticin per ml
(Gibco). Rat basophilic leukemia (RBL) and COS-7 cells were cultured in Dul-
becco’s modified Eagle’s medium supplemented with 10% fetal calf serum, 2 mM
L-glutamine, penicillin, and streptomycin.
COS-7 cells were transfected by the DEAE-dextran technique (16). T-Ag
Jurkat cells (106) were electroporated (at 260V and 960 mF) in 0.5 ml of RPMI
1640 supplemented with 20% fetal calf serum in a Gene Pulser cuvette (Bio-
Rad).
The anti-Vav monoclonal antibody (MAb) was purchased from Upstate Bio-
technology. MAbs against myc and hemagglutinin (HA) epitopes were pur-
chased from the American Type Culture Collection (9E10-CRL 1725) and
Babco (12CA5), respectively. The anti-CD3 MAb (UCHT1) was provided by G.
Bismuth (Paris, France), and anti-CD28 was provided by D. Olive (Marseille,
France).
Rabbit polyclonal anti-hSiah2 antibodies were generated against a peptide
corresponding to aa 150 to 162 of hSiah2 (Syntem).
Immunofluorescence staining. RBL or Jurkat cells were fixed in phosphate-
buffered saline (PBS) plus 3% paraformaldehyde and permeabilized in PBS plus
0.1% Triton X-100. The coverslips were rinsed and blocked for 10 min in PBS
plus 0.2% bovine serum albumin prior to incubation with antibodies. Fixed cells
were incubated simultaneously with both primary antibodies (anti-Vav MAb and
anti-hSiah2 sera, 1:500) for 30 min and then incubated with donkey anti-mouse
antibody coupled to Texas red (1:250) and with donkey anti-rabbit antibody
coupled to fluorescein isothiocyanate (1:100). For peptide-blocking experiments,
the anti-hSiah2 antiserum was depleted by incubation for 1 h at 4°C with a
nitrocellulose membrane saturated with 1 mg of the immunizing peptide prior to
immunofluorescence staining. The coverslips were mounted in Mowiol with
Dabco antifading (Hoechst, Frankfurt, Germany). The staining pattern was
analyzed by confocal laser-scanning microscopy (Bio-Rad) at two different emis-
sion wavelengths (fluorescein isothiocyanate, 522/535; Texas red, 605/632), and
colocalization was performed by further analysis of superposed images that were
obtained as TIFF files.
In vitro binding and immunoprecipitation experiments. Glutathione S-trans-
ferase (GST) fusion proteins were induced and purified as previously described
(58). Lysates from lysis of 107 Jurkat cells in Nonidet P-40 (NP-40) buffer (10
mM Tris-HCl [pH 7.4], 150 mM NaCl, 10% glycerol, 1% NP-40, 1 mM dithio-
threitol, 1% aprotinin, 1 mM phenylmethylsulfonyl fluoride [PMSF], 1 mg of
pepstatin per ml, 1 mg of leupeptin per ml) were incubated for 2 h with fusion
protein bound to glutathione-coupled agarose beads (Pharmacia). The beads
were washed five times in NP-40 lysis buffer, resuspended in Laemmli buffer and
fractionated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) (12% polyacrylamide). The proteins were electrotransferred to nitrocel-
lulose membranes and probed with primary antibody (MAb anti-Vav diluted
1:1,000 in Tris-buffered saline [pH 7.6]–0.05% Tween 20) followed by secondary
antibody conjugated to horseradish peroxidase and then revealed with the ECL
kit (Amersham).
For coimmunoprecipitation experiments, COS-7 and T-Ag Jurkat cells were
lysed in NP-40 buffer approximately 48 h after transfection and lysates were
incubated at 4°C with anti-myc tag MAb for 4 h followed by protein A-Sepharose
(Pharmacia) for 1 h. The precipitates were analyzed as described below.
Kinase assays. Subconfluent COS-7 or T-Ag Jurkat cells were transfected as
described previously (16). After transfection, the cells were cultured for 48 h,
washed with PBS, and lysed at 4°C in a buffer containing 20 mM Tris-HCl (pH
7.5), 137 mM NaCl, 2 mM EDTA, 1% Triton X-100, 25 mM b-glycerophosphate,
1 mM sodium vanadate, 1 mM PMSF, 20 mg of aprotinin per ml, and 20 mg of
leupeptin per ml. Clear lysates were immunoprecipitated by incubation with
anti-HA antibodies (12CA5) for 2 h at 4°C. Immunocomplexes were recovered
with Gamma bind Sepharose beads (Pharmacia) and washed twice in lysis buffer
and once more in kinase buffer (25 mM HEPES [pH 7.5], 25 mM MgCl2, 25 mM
b-glycerophosphate, 1 mM sodium vanadate, 1 mM PMSF, 20 mg of aprotinin
per ml, 20 mg of leupeptin per ml). JNK activity was determined after resuspen-
sion of the immunocomplexes in 50 ml of kinase buffer containing 10 mCi of
[g-32P]ATP (3,000 Ci/mmol) per reaction and 50 mM unlabeled ATP, with 1 mg
of GST–c-Jun fusion protein as a substrate (16). After 30 min at 30°C, the
reactions were stopped by the addition of 50 ml of sample buffer, and the
products were boiled at 95°C for 5 min and resolved by SDS-PAGE (12%
polyacrylamide). Autoradiography was performed with the aid of an intensifying
screen and quantitated with a PhosphorImager (Molecular Dynamics).
Luciferase assays. T-Ag Jurkat cells (107) were electroporated with 5 mg of the
reporter plasmid pNFAT-Luc together with 20 mg of pEF-Vav-Myc with or
without 20 mg of pCAN-v240/pCAN-v460. Similar amounts of empty vector were
used as a control. At 24 h after transfection, 106 cells were either left unstimu-
lated or stimulated in growth medium containing anti-CD3 MAb (10 mg/ml) plus
anti-CD28 (10 mg/ml). After 8 h at 37°C, the cells were lysed in 200 ml of buffer
containing 100 mM KPO4 (pH 7.8), 1 mM dithiothreitol, and 0.5% Triton X-100.
Lysate (20 ml) was mixed with 100 ml of assay buffer (200 mM KPO4 [pH 7.8], 10
mM ATP, 20 mM MgCl2) followed by 100 ml of 1 mM luciferin. Luciferase
activity was determined in triplicate and expressed as arbitrary units (AU) after
normalization to the b-galactosidase values to correct for variation in transfec-
tion efficiency.
RESULTS
hSiah2, a new Vav-interacting protein. To identify pro-
teins implicated in Vav signaling pathways, we used the yeast
two-hybrid system with the SH2 and SH3 domains of Vav
(SHVAV, aa 623 to 837) fused to the DNA-binding domain
of LexA as a bait to screen a Jurkat T-cell cDNA library. Of
approximately 4 3 106 clones screened, 450 positive clones
were analyzed for their specific interaction with SHVAV. Of
these, six clones from three independent LexA fusions
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strongly interacted with SHVAV. Sequence analysis of the
yeast plasmids showed that they were identical to hSiah2
(37). The previously described Sina/Siah proteins contain an
N-terminal cysteine-rich region (C3HC4) called the ring fin-
ger domain and, in the C-terminal region, two basic clusters
close to a bipartite nuclear localization sequence (12, 20)
(Fig. 1A). The two largest clones isolated, v240 and v472 (aa
13 to 324), contained almost the entire coding sequence
of hSiah2, whereas the shortest one, v460 (aa 105 to 324),
maintained only the C-terminal 11 aa of the ring finger do-
main of hSiah2. A strong interaction was also detected when
v240 was expressed as a fusion to the LexA DNA-binding
domain and SHVAV was expressed as a fusion to the Gal4
activation domain. Full-length hSiah2 was isolated and, as
expected, interacted with SHVAV. As indicated in Fig. 1B,
no transactivation was observed when different hSiah2
clones were coexpressed with unrelated fusion plasmids
(pLexA-Rasv12 or pLexA-lamin). When hSiah2 clones were
tested with Grb2, which, like Vav, has closely spaced SH3-
SH2-SH3 domains (63), no reporter gene activity was de-
tected (Fig. 1B), suggesting that the hSiah2-SHVAV inter-
action requires rather specific SH3-SH2-SH3 sequences.
Finally, when v240 was cloned in both pLexA and pGAD, a
strong self-interaction was observed in the yeast trap assay,
suggesting a possible dimerization process for hSiah2 (Fig.
1B). Taking account of hSiah1/hSiah2 homology, the expected
interaction between SHVAV and hSiah1 was also observed
(Fig. 1B).
hSiah2 interacts with Vav in vitro, and the proteins coim-
munoprecipitate from COS-7 and Jurkat T cells. The interac-
tion between Vav and hSiah2 was then confirmed by an in vitro
binding assay. Different hSiah2 regions fused to GST (Fig. 2A)
were expressed in Escherichia coli, and the affinity-purified
proteins were tested for their ability to bind endogenous Vav
from Jurkat T-cell lysates. Consistent with the yeast two-hybrid
assay, both hSiah2 fusion proteins, containing an almost full-
length hSiah2 (GST-v240) or only the C-terminal portion of
hSiah2 (GST-v460), were able to interact with Vav (Fig. 2B).
To delineate the region of hSiah2 responsible for this interac-
FIG. 1. Vav interacts with hSiah2 in the yeast two-hybrid system. (A) Sche-
matic representation of hSiah2 and the clones obtained from the two-hybrid
screening. (B) Protein interaction in the two-hybrid system. The L40 reporter
strain was cotransformed with 1 mg of the indicated pLex- and pGAD-derived
plasmids, and interactions were detected as b-galactosidase activity.
FIG. 2. In vitro binding between hSiah2 and Vav. (A) Schematic represen-
tation of GST-hSiah2 fusion proteins. (B) Binding of Vav to GST-hSiah2 fusion
proteins. Total-cell lysates from 107 Jurkat T cells were incubated at 4°C for 2 h
with 1 mg of the fusion proteins or GST alone. (C) (Top) Lysates from unstimu-
lated (0 min) and CD3-plus-CD28-stimulated (1 min and 30 min) Jurkat T cells
(107) were incubated with 1 mg of GST-v240. The resulting complexes were
resolved by SDS-PAGE, and the Western blot (Wb) was developed with anti-Vav
MAb. The left-hand lane contains total lysate from 2 3 105 cells. (Bottom)
Western blot analysis with antiphosphotyrosine antibody (anti-PTyr) of the total-
cell extracts used in the top panel.
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tion, we produced C-terminal deletions of 38 aa (GST-v240Da)
or 164 aa (GST-v240Db) of clone v240. With the latter dele-
tion, the interaction with Vav could no longer be detected (Fig.
2B). A similar result was also obtained in the yeast two-hybrid
assays (results not shown). This indicates that the domain of
hSiah2 responsible for the interaction with Vav lies between aa
160 and 286 of hSiah2 and does not involve the ring finger
domain, which is known to be a protein-protein interaction
domain (7). We used the yeast two-hybrid assay to delineate
the hSiah2-binding site in the Vav molecule. None of the
individual SH3 or SH2 domains nor subdomains such as N-ter-
minus–SH3-SH2 or SH2-SH3–C-terminus were able to inter-
act with hSiah2 (clone v240), indicating that a conformation
present in the complete SHVAV region was required for bind-
ing to hSiah2 (data not shown). The association between Vav
and hSiah2 was not modulated by cellular activation. Lysates
from unstimulated or anti-CD3- plus anti-CD28-stimulated Ju-
rkat cells exhibited the same amount of Vav proteins bound to
the GST-v240 fusion protein (Fig. 2C, top), despite an in-
creased Vav tyrosine phosphorylation after activation (Fig. 2C,
bottom).
To further analyze the association between hSiah2 and Vav,
both COS-7 and T-Ag Jurkat cells were transfected with ex-
pression vectors encoding Vav alone, myc epitope-tagged
hSiah2 alone (v240 or v460), or myc epitope-tagged hSiah2
together with Vav. This approach was rendered necessary be-
cause the anti-hSiah2 antiserum did not allow us to immuno-
precipitate the protein. The lysates were immunoprecipitated
with anti-myc antibody, and the immunocomplexes were ana-
lyzed for the presence of Vav and hSiah2 proteins. As shown in
Fig. 3, Vav could be detected in the immunocomplexes derived
from both cell types cotransfected with Vav and either the v240
or v460 clones. As expected, Vav could not be detected in
anti-myc immunoprecipitates from cells transfected with either
myc-hSiah2 (v240 or v460) or Vav constructs alone or from
hSiah2-plus-Vav transfectants immunoprecipitated with un-
related sera (Fig. 3A and B, top, and data not shown). We
carried out reciprocal immunoprecipitation experiments (IP
anti-Vav in Vav and myc-hSiah2 transfected cells), but in spite
of the presence of similar levels of the proteins, the level of
myc-tagged hSiah2 detected was too low to be meaningful
(data not shown). This discrepancy might be because the anti-
Vav antibody interfered with hSiah2-Vav interaction.
Colocalization of Siah and Vav. Further support for the in
vivo Vav-hSiah2 interaction was obtained by studying the sub-
cellular localization of endogenous Siah and Vav by immuno-
fluorescence labeling. We used both Jurkat T cells and RBL
cells, whose adherence properties facilitate the visualization of
subcellular structures. In both cell models, Siah and Vav were
detected mainly in the cytoplasm, although a weak signal was
observed in the nucleus (Fig. 4C and E). No staining was
detected with the preimmune Siah antiserum followed by the
secondary antibody (Fig. 4A) or when anti-Siah antiserum was
depleted with an excess of the immunizing peptide prior to
incubation with the cells (Fig. 4B). Although previous studies
indicated that Drosophila Sina was a nuclear protein (12) and
that in transfected COS-7 cells hSiahs were distributed in dis-
crete cytoplasmic particles (38), we found that endogenous
Siah was evenly distributed in the cytoplasm, with a pro-
nounced perinuclear localization. Interestingly, this region is
the major site of colocalization of the two proteins (Fig. 4G).
After stimulation of RBL cells via aggregation of FcεRI, a
partial nuclear translocation of Vav but not Siah could be
detected (Fig. 4D and F), leaving the major colocalization site
around the nucleus (Fig. 4F and H). These data provide fur-
ther evidence for the existence of a cytoplasmic in vivo complex
between Vav and hSiah2 and reinforce the coimmunoprecipi-
tation results showing that the interactions were not induced
during the experimental procedure, although a specific confor-
mation was required to detect this interaction.
hSiah2 inhibits Vav-mediated NFAT activation. It has been
reported that TCR stimulation contributes to IL-2 production
through activation of different transcription factors, including
NFAT and AP1 (55). Overexpression of Vav leads to an in-
creased basal NFAT transcriptional activity, which is further
enhanced by TCR stimulation (36, 68). We tested whether
hSiah2 may also be involved in Vav-mediated NFAT activa-
tion. To this end, we overexpressed Vav either alone or in
combination with myc-tagged hSiah2 (clone v240 or v460) in
T-Ag Jurkat cells and examined their relative effects on the
activity of a NFAT-luciferase reporter construct (NFAT-luc)
containing a trimer of an IL-2-derived cis-acting element
cloned upstream of the luciferase reporter gene. The activation
of this promoter requires cooperative binding of NFAT pro-
teins and AP1 transcription factors (55). As expected, Vav
overexpression led to a significant induction of the basal tran-
FIG. 3. hSiah2 interacts with Vav in mammalian cells. COS-7 cells (A) or T-Ag Jurkat cells (B), transiently transfected with 4 and 20 mg, respectively, of either
pKES-Vav (Vav), myc-tagged pCAN-v240 (myc-v240), or pCAN-v460 (myc-v460) alone or with a combination of the vectors (Vav1myc-v240; Vav1myc-v460), were
lysed in NP-40 buffer and immunoprecipitated with anti-myc MAb and protein G-Sepharose beads. Immunoprecipitates (IP) were detected with anti-Vav MAb (top).
Expression of transfected hSiah2 (clones v240 and v460) was verified by reprobing the nitrocellulose membrane with anti-myc MAb (bottom). Wb, Western blot.
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scriptional activity of the NFAT reporter construct relative to
the control vector, which was further increased by CD3 plus
CD28 stimulation (Fig. 5A). Coexpression of hSiah2 (clone
v240) with Vav inhibited the Vav-induced NFAT activity in
unstimulated cells, and a consistent reduction was observed in
CD3- plus CD28-stimulated cells. On the other hand, no inhi-
bition was observed when Vav was coexpressed with clone
v460. Expression of either v240 or v460 alone did not signifi-
cantly modify basal and CD3- plus CD28-stimulated NFAT
activity (Fig. 5A).
A similar result was also observed with the full-length
hSiah2. As reported in Fig. 6, hSiah2 inhibited Vav-mediated
NFAT induction in a dose-dependent manner. Interestingly,
hSiah1, which is highly homologous to hSiah2 apart from the
N-terminal region, did not exhibit any significant inhibition of
Vav-mediated NFAT activity (Fig. 6). Since an intact N-termi-
nal region of hSiah2 is required for the inhibition of Vav-
induced NFAT activity, this inhibitory effect may reflect an
association of hSiah2 and Vav in a complex involving the N-
terminal region of hSiah2 with an as yet uncharacterized pro-
FIG. 4. Immunolocalization of Vav and hSiah2 by confocal immunofluorescence microscopy. RBL cells were labeled with preimmune Siah antiserum (A), Siah
antiserum depleted of the immunizing peptide (B), anti-Vav MAb (C and D), and anti-hSiah2 rabbit polyclonal antibody (E and F) as described in Materials and
Methods. Colocalization of red fluorescence from Vav and green fluorescence from hSiah2 produced a yellow signal, indicating an overlap in the distribution of the
two proteins (G and H). In panels D, F, and H, cells were stimulated (Stim.) by FcεRI cross-linking. Panels A and B were obtained with a much higher transmission
rate in order for the signal to be detectable.
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tein. The N-terminal region of hSiah1, which showed only 53%
homology to its counterpart in hSiah2, could not mediate such
an interaction and hence could not have any inhibitory role.
hSiah2 inhibits onco-Vav-mediated JNK activation. Recent
evidence showed that activated Vav catalyzes GDP-GTP ex-
change on Rac1 and that Rac1-GTP stimulates the kinase
activity of JNK (17, 18). The finding that hSiah2 interacted
with Vav led us to investigate whether hSiah2 may modulate
Vav-induced JNK activity. To this end an HA-tagged JNK and
the oncogenic form of Vav (onco-Vav), which constitutively
activates JNK, were cotransfected in COS-7 or T-Ag Jurkat
cells, alone or together with myc epitope-tagged hSiah2 (v240
or v460 clones). As shown in Fig. 7A and C, coexpression of
v240 with onco-Vav and HA-JNK abrogated almost com-
pletely the onco-Vav-induced JNK activation (three- to four-
fold), which returned to levels found in cells transfected only
with JNK. In contrast, cotransfection of the N-terminally de-
leted hSiah2 (v460), which still binds to Vav, did not modify the
activation of JNK by onco-Vav despite similar levels of expres-
sion of the different proteins (Fig. 7B and D). These results
favor an inhibitory role for hSiah2 in the onco-Vav-induced
JNK activation and agree with the inhibitory effect observed
with clone v240 but not v460 in Vav-induced NFAT activity.
hSiah2 does not decrease the stability of Vav protein. Both
Sina and murine Siah2 have been implicated in regulating the
proteasomal degradation of diverse proteins to which they bind
(38, 45, 66). This function seems to be associated with the
amino-terminal 114 aa of the Sina and Siah proteins, including
the ring finger domain, which interacts in a yeast trap assay
with ubiquitin-conjugating enzymes and Ubc9 homologs (38,
45, 66). To investigate whether hSiah2 expression affects Vav
protein stability, we performed a pulse-chase experiment (Fig.
8). COS-7 cells were transiently transfected with myc epitope-
tagged Vav alone or together with myc epitope-tagged hSiah2
(v240 or v460). Cotransfection of Vav with either v240 or v460
did not accelerate Vav degradation (Fig. 8). We also observed
that the half-life of Siah was somehow much shorter than that
of Vav. Taken together, these findings exclude the notion that
hSiah2 could alter Vav stability. The evidence that the N-
terminal deletion mutant of hSiah2 fails to inhibit Vav-induced
NFAT and JNK activity prompted us to ask whether the in-
hibitory mechanism of hSiah2 could be mediated by the deg-
radation of one or more components of the signal transduction
pathways induced by Vav. JNK assays with COS-7 cells co-
transfected with hSiah2 and Vav showed that JNK inhibition
did not occur via the degradation of either JNK, Rac1, or c-Jun
(data not shown). Additionally, treatment of the cells with the
proteasome inhibitor LLnL (N-acetyl-Leu-Leu-norleucinal) or
lactacystin at 50 mM did not modify the inhibitory effect of
hSiah2 in NFAT or JNK assays (data not shown). Together,
these data demonstrate that the inhibitory mechanism of
hSiah2 might not involve a proteasome degradation pathway.
DISCUSSION
We report here the identification of a new Vav-associated
protein, hSiah2, a human homolog of Drosophila Seven in
absentia (Sina). Sina was initially described as a nuclear pro-
tein implicated in the specification of the R7 photoreceptor
cell through the Ras1-MAPK signaling cascade (4, 52), com-
prising the tyrosine kinase Sevenless, Grb2, and Raf (26, 28, 44,
50, 61). Sina interacts with ubiquitin-conjugating enzymes that
FIG. 5. Vav-mediated NFAT activation is inhibited by hSiah2. (A) T-Ag
Jurkat cells (107) were transfected with NFAT and pSVb-galactosidase reporter
plasmids (5 and 1 mg, respectively) and 20 mg of either an empty vector (vector),
pEF-Vav (Vav), pCAN-v240 (v240), pCAN-v460 (v460), or a combination of the
vectors as indicated. A total of 106 cells were either left unstimulated or stimu-
lated after 24 h with anti-CD3 plus anti-CD28 for 8 h. Luciferase activity was
measured and corrected for b-galactosidase activity, and the results were ex-
pressed as average fold induction relative to unstimulated cells transfected with
the empty vector. The data are representative of four independent experiments.
The basal activity and the maximum NFAT responses were approximately 600
and 2 3 105 AU, respectively. (B) T-Ag Jurkat cell lysates from panel A were
analyzed by immunoblotting for expression of Vav and hSiah2 (v240 and v460).
Wb, Western blot.
FIG. 6. Overexpression of hSiah2 inhibits Vav-induced NFAT activity in a
dose-dependent manner. T-Ag Jurkat cells (107) were transfected with NFAT
and pSVb-galactosidase reporter plasmids (5 and 1 mg, respectively), 10 mg of
pEF-Vav (Vav), and increasing concentrations of pBK-CMV hSiah2 or pBK-
CMV hSiah1 as indicated. Luciferase activity was determined and normalized to
b-galactosidase activity to correct for transfection efficiency.
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are able to target TTK, a transcriptional repressor of neuronal
cell fate, to the degradative pathway (45, 66). Recently, Siah
proteins were found to bind either to the cytoplasmic domain
of the receptor for netrin 1 (DCC, deleted in colorectal cancer)
or to the nuclear receptor corepressor (N-CoR) and to medi-
ate their degradation via a proteasome-dependent mechanism
(38, 72). Additionally, it has been reported that the p53-induc-
ible hSiah1 is a negative regulator of cell proliferation and that
its interaction with BAG1, a ubiquitin-like Hsp70-Hsc70-reg-
ulating protein, abrogated this antiproliferative role (47). The
FIG. 7. Inhibitory effect of hSiah2 on onco-Vav-mediated JNK activation. COS-7 (A) or T-Ag Jurkat (C) cells were transfected with 1 mg (A) or 5 mg (C) of
pcDNA3-HA-JNK together with 3 mg (A) or 15 mg (C) of expression vectors containing cDNA for the indicated plasmids. The total amount of transfected DNA was
kept constant by using empty pcDNA3 vector. COS-7 cells treated with 1 mg of anisomycin per ml for 20 min were used as a control. The kinase reaction was performed
in anti-HA immunoprecipitates from the corresponding cellular lysates with purified GST–c-Jun as a substrate (A and C, top panels). The levels of HA-JNK protein
were confirmed by Western blot (Wb) analysis with anti-HA antibody (bottom panels). Values in the histogram represent the means and the standard errors of four
independent experiments. COS-7 (B) and T-Ag Jurkat (D) cell lysates from panels A and C were analyzed by immunoblotting for expression of Vav and
myc-epitope-tagged hSiah2 (v240 and v460). The additional bands in these blots could be due to degradative events caused by onco-Vav overexpression.
FIG. 8. hSiah2 does not decrease the half-life of Vav. COS-7 cells were cotransfected with 4 mg of myc-tagged pEF-Vav (myc-Vav) and pCAN-v240 (myc-v240) or
pCAN-v460 (myc-v460). At 48 h after transfection, the cells were pulse-labeled for 1 h with [35S]methionine, chased with cold methionine for the indicated times, and
then lysed as described in Materials and Methods. Vav and hSiah2 proteins were immunoprecipitated (IP) with anti-myc antibody and analyzed by SDS-PAGE and
autoradiography.
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high level of evolutionary conservation of the Siah and Sina
proteins between humans, mice, and Drosophila (76%) sug-
gests that these proteins may play a crucial role in cellular
processes such as proliferation, differentiation, and survival.
Through a two-hybrid screen in yeast, we detected an inter-
action between Vav and hSiah2 (Fig. 1), which was confirmed
by using hSiah2 GST fusion proteins (Fig. 2) and also by
performing coimmunoprecipitation experiments with cotrans-
fected COS-7 and Jurkat T cells (Fig. 3). We also found, by
immunofluorescence microscopy, a colocalization of Siah and
Vav in the cytoplasm of hematopoietic cells, where Siah is
predominantly observed (Fig. 4). Although the original studies
reported a nuclear localization signal for Sina, a somehow
controversial distribution in cytoplasmic particles has been re-
ported for transfected hSiah proteins (12, 38). Both Vav and
hSiah2 contain nuclear localization sequences which could me-
diate the translocation of one or both proteins to the nucleus.
Several Vav-interacting nuclear proteins, such as Ku70 (58),
ENX-1 (32) and hnRNP C (60), have been reported, and the
presence of Vav in the nucleus has already been documented
(14). In the present study, we showed some nuclear accumu-
lation of Vav in RBL cells after FcεRI stimulation that did not
correlate with a delocalization of hSiah2, indicating that the
functional relevance of the Vav-hSiah2 interaction should be
cytoplasmic rather than nucleoplasmic. On the other hand, we
reported that tyrosine phosphorylation of Vav did not influ-
ence the Vav-hSiah2 interaction (Fig. 2). Nevertheless, the
mechanism by which Vav might link receptor-mediated signals
to the nucleus is not yet established, and the interaction be-
tween Siah and Vav could be regulated within the cell by an as
yet uncharacterized stimulus, offering to Siah the possibility of
modulating some Vav functions.
The Vav-hSiah2 interaction requires a specific conforma-
tional structure of Vav present in the complete SH3-SH2-SH3
domain (Fig. 2). Residues 160 to 286 in the C-terminal region
of hSiah2 are also involved in binding to Vav but do not
contain a proline-rich sequence expected to interact with Vav
SH3 domains. Therefore, the interaction between Vav and
hSiah2 probably corresponds to a different protein-protein in-
teraction. Interestingly, Ku70 protein does not use its proline-
rich motif in binding to the carboxy-terminal SH3 domain of
Vav (58), and Cbl-b needs the complete SH3-SH2-SH3 do-
main of Vav for correct binding (10). We also have evidence,
obtained with the two-hybrid system, indicating that hSiah2
could dimerize through a region (aa 105 to 160) adjacent to the
Vav-interacting domain (data not shown). It will be interesting
to investigate whether the two interactions Vav-hSiah2 and
hSiah2-hSiah2 are simultaneous or competitive. In this way, it
is plausible that the formation of the complexes is controlled by
substrate availability. Although the ring finger domains are
generally involved in protein-protein interactions, neither Vav-
hSiah2 nor hSiah2-hSiah2 interactions require this domain
(Fig. 2 and data not shown).
The expression of hSiah2 impaired the transcriptional activ-
ity of NFAT reporter gene expression induced by Vav in Jurkat
T cells (Fig. 5). NFAT is an important activator of gene tran-
scription of cytokines, such as IL-2, IL-3, IL-4, and tumor
necrosis factor alpha (55). This activation is mediated by co-
operative binding of NFAT proteins with transcription factors
of the AP-1 family (Jun-Fos complex) (54). It has been shown
that Vav activates IL-2 gene expression and synergizes with the
TCR stimulation in inducing NFAT-dependent transcription
(36, 68). Our results confirm these findings and further dem-
onstrate that coexpression of hSiah2 and Vav causes a signif-
icant decrease of NFAT reporter activity that is more pro-
nounced in TCR-stimulated cells. Interestingly, neither the
N-terminal deletion mutant of hSiah2 nor a member of the
Siah family, hSiah1, is able to inhibit Vav-induced NFAT ac-
tivity (Fig. 5 and 6). It is known that hSiah1 and hSiah2 pro-
teins exhibit striking homology, diverging significantly only at
their N termini. Together, these results favor a model in which
hSiah2 modulation of Vav activation might be dependent on
the formation of a specific signaling complex with other effec-
tors, probably through the N-terminal region of hSiah2, but not
of hSiah1, which in turn functions cooperatively to influence
the downstream events leading to IL-2 gene regulation. We
also observed that hSiah2 was able to block the onco-Vav-
induced JNK stimulation in cotransfected COS-7 and T-Ag
Jurkat cells (Fig. 7). It has been reported that onco-Vav leads
to the stimulation of GDP-GTP exchange in Rac1, a protein
implicated in cell proliferation and cytoskeletal organization
(5, 56, 57) as well as in the activation of the JNK cascade (16).
This inhibition could not be obtained with the N-terminal
deletion mutant of hSiah2 (aa 105 to 324, clone v460). Al-
though there are controversial data reporting, on the one hand,
onco-Vav constitutive activation of Rac proteins and sequen-
tial JNK activation after transfection in T-cell lines (17, 18)
and, on the other hand, unimpaired JNK activity in T cells
isolated from vav2/2 animals (24, 35), the implication of Sina
in the Drosophila Ras-MAPK-induced signaling and the pres-
ence of Vav in both pathways involving Grb2 (53, 70) and Rac1
(18, 29, 51) suggest that hSiah2 interaction with Vav might also
impair diverse signal transduction pathways. This correlates
with recent findings demonstrating that several pathways could
be implicated in JNK activation in T cells (39, 56).
Additionally, the inhibitory activity of hSiah2 seems to be
independent of the proteolytic mechanism previously de-
scribed for Sina and mSiah2 (38, 45, 66, 71). Our own exper-
iments showed that hSiah2 did not modify the half-life of Vav,
and the use of proteasomal blocking agents showed that the
inhibitory effect of hSiah2 on NFAT activity and JNK pathways
does not seem to be mediated via ubiquitin-proteasome-de-
pendent degradation (data not shown). Studies to identify
hSiah2-interacting proteins are under way and will be helpful
to clarify its inhibitory role.
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